New research says GLP-1 receptor agonist therapy could lower the risk of fatal or non-fatal stroke and death from cardiovascular causes in people with type 2 diabetes.
The researchers analysed cardiovascular trials to compare the drug with a placebo in the treatment of people with type 2 diabetes.
The analysed data was collected from more than 52,000 participants across six multinational double-blind, randomised, placebo-control trials.
PubMed and Embase were used by the research team, from the Second Hospital of Lanzhou University in China, to pinpoint relevant randomised controlled trials from inception to June 2019, which assessed the effect of GLP-1 receptor agonists on cardiovascular events in people with type 2 diabetes.
All participants in these relevant trials were given either the GLP-1 therapy or a placebo. The cardiovascular outcomes consisted of death from cardiovascular causes, fatal or non-fatal myocardial infarction and fatal or non-fatal stroke.
The researchers summarised: “The results indicated that GLP-1 receptor agonists reduced the risk of death from cardiovascular causes (RR: 0.90; 95% CI: 0.83–0.97; P = 0.004) and fatal or non-fatal stroke (RR: 0.85; 95% CI: 0.77–0.94; P = 0.001) compared with the placebo controls. But GLP-1 receptor agonists did not significantly alter the fatal or non-fatal myocardial infarction compared with the placebo (RR: 0.91; 95% CI: 0.82 – 1.01; P = 0.06).”
They added: “We concluded that GLP-1 receptor agonist therapy could reduce the risk of death from cardiovascular causes and fatal or non-fatal stroke compared with the placebo in the treatment of T2DM patients in trials with cardiovascular outcomes.”
The study was published by BMC Endocrine Disorders.